FDA mulls compounding for peptides previously flagged over safety risks BioSpace The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and TB 500: Injury Healing Peptides Jonathan L. Glashow posted on the topic LinkedIn Oral Peptides: FAQs on Bioavailability, Safety, and Clinical Use AJMC RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step